Search

Your search keyword '"Wysham, Carol H"' showing total 6 results
Start Over Author "Wysham, Carol H" Journal clinical diabetes
6 results on '"Wysham, Carol H"'

1. Consensus report: diabetes performance measures: current status and future directions

Author

O'Connor, Patrick J., Bodkin, Noni L., Fradkin, Judith, Glasgow, Russell E., Greenfield, Sheldon, Gregg, Edward, Kerr, Eve A., Pawlson, L. Gregory, Selby, Joseph V., Sutherland, John E., Taylor, Michael L., and Wysham, Carol H.

Subjects
United States. Centers for Disease Control and Prevention -- Reports, United States. Veterans Health Administration -- Reports, Cholesterol -- Measurement -- Reports, Diabetes therapy -- Quality management -- Measurement -- Reports, Patient compliance -- Measurement -- Reports, Diabetes -- Care and treatment -- Measurement -- Reports, Practice guidelines (Medicine) -- Measurement -- Reports, Medical records -- Measurement -- Reports, Health, American Diabetes Association -- Reports
Abstract

OVERVIEW: Just as treatment guidelines for diabetes care were at the forefront of medical guideline development, (1) diabetes has been a prominent focus of performance measurement and quality improvement initiatives [...]

Published
2011
Full Text
View/download PDF

6. Safety and Efficacy of Insulin Degludec/ Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications.

Author

Wysham, Carol H., Campos, Carlos, and Kruger, Davida

Subjects
*COMBINATION drug therapy, *INSULIN, *TYPE 2 diabetes, *TREATMENT effectiveness, *GLUCAGON-like peptide-1 agonists, *PHARMACODYNAMICS
Abstract

Novel co-formulations of basal insulin analogs and glucagon-like peptide-1 (GLP-1) receptor agonists have provided new options for patients with type 2 diabetes who are not reaching recommended glycemic targets. The components of currently available co-formulations (insulin degludec/ liraglutide [IDegLira,] and insulin glargine U100/lixisenatide [iGlarLixi]) act synergistically to address multiple pathophysiologic defects while minimizing the side effects associated with either component when used alone. In Europe, these products are approved for use in patients on regimens of one or more oral antidiabetic drugs; in the United States, they are indicated for use as an adjunct to diet and exercise in patients with type 2 diabetes inadequately controlled with either basal insulin or their respective GLP-1 receptor agonist component. This article reviews key clinical trials in which these products were initiated in insulin-naive patients and describes how they can be safely and effectively titrated in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results